Zhao Hui, Wang Jundong, Li Shuting, Bao Ying, Zheng Xiaoxia, Tao Yuan, Wang Hong
Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, China.
Department of Ophthalmology, Fei County People's Hospital of Shandong, Linyi, Shandong, China.
Front Med (Lausanne). 2023 Mar 9;10:1090964. doi: 10.3389/fmed.2023.1090964. eCollection 2023.
The objective of the study was to investigate the effectiveness of aflibercept and panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy (PDR).
A retrospective analysis was performed on 59 patients (59 eyes) with high-risk PDR who were treated with aflibercept and PRP between January 2018 and December 2019. The best corrected visual acuity (BCVA), central foveal thickness (CFT), and retinal vein diameter post-treatment were compared to those before the treatment.
The best corrected visual acuity (BCVA) at 6 months (0.49 ± 0.14 logMAR), 12 months (0.54 ± 0.15 logMAR), 18 months (0.48 ± 0.15 logMAR), and 24 months (0.51 ± 0.15 logMAR) post-treatment were superior to the pre-treatment measurement (0.65 ± 0.18 logMAR). The central foveal thickness (CFT) at 6 months (310.67 ± 52.53 μm), 12 months (295.98 ± 45.65 μm), 18 months (282.56 ± 43.57 μm), and 24 months (281.53 ± 51.16 μm) post-treatment were lower than the pre-treatment measurement (456.53 ± 51.49 μm); the retinal vein diameter at 12 months (310.13 ± 24.60 μm), 18 months (309.50 ± 31.58 μm), and 24 months (317.00 ± 27.54 μm) post-treatment were lower than the pre-treatment measurement (361.81 ± 30.26 μm).
Aflibercept intravitreal injection and panretinal photocoagulation may morphologically reverse retinal vein diameter and venous beading in high-risk proliferative diabetic retinopathy.
本研究的目的是探讨阿柏西普和全视网膜光凝（PRP）治疗增殖性糖尿病视网膜病变（PDR）的有效性。
对2018年1月至2019年12月期间接受阿柏西普和PRP治疗的59例高危PDR患者（59只眼）进行回顾性分析。将治疗后的最佳矫正视力（BCVA）、中心凹厚度（CFT）和视网膜静脉直径与治疗前进行比较。
治疗后6个月（0.49±0.14 logMAR）、12个月（0.54±0.15 logMAR）、18个月（0.48±0.15 logMAR）和24个月（0.51±0.15 logMAR）的最佳矫正视力（BCVA）优于治疗前测量值（0.65±0.18 logMAR）。治疗后6个月（310.67±52.53μm）、12个月（295.98±45.65μm）、18个月（282.56±43.57μm）和24个月（281.53±51.16μm）的中心凹厚度（CFT）低于治疗前测量值（456.53±51.49μm）；治疗后12个月（310.13±24.60μm）、18个月（309.50±31.58μm）和24个月（317.00±27.54μm）的视网膜静脉直径低于治疗前测量值（361.81±30.26μm）。
玻璃体内注射阿柏西普和全视网膜光凝可能在形态学上逆转高危增殖性糖尿病视网膜病变的视网膜静脉直径和静脉串珠样改变。
